We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

173 hedge funds and large institutions have $315M invested in Rocket Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 62 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

98% more call options, than puts

Call options by funds: $2.87M | Put options by funds: $1.45M

35% more capital invested

Capital invested by funds: $233M → $315M (+$81.8M)

0.53% more ownership

Funds ownership: 88.98% → 89.52% (+0.53%)

2% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 62

12% less funds holding

Funds holding: 196 → 173 (-23)

44% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 50

Holders
173
Holders Change
-23
Holders Change %
-11.73%
% of All Funds
2.27%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
28
Increased
61
Reduced
62
Closed
50
Calls
$2.87M
Puts
$1.45M
Net Calls
+$1.42M
Net Calls Change
+$925K

Top Buyers

1
MAM
Monaco Asset Management
Monaco
+$7.68M
2
Citadel Advisors
Citadel Advisors
Florida
+$4.77M
3
Millennium Management
Millennium Management
New York
+$3.85M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.77M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.72M

Top Sellers

1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$2.69M
2
CSS
Cubist Systematic Strategies
Connecticut
-$1.76M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$1.68M
4
WP
Woodline Partners
California
-$1.6M
5
N
Nuveen
North Carolina
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$57.7M – – –
MC
2
Maverick Capital
Texas
$27.6M +$329K +104,531 +1%
BlackRock
3
BlackRock
New York
$23.2M -$990K -314,305 -4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$22.5M +$2.42M +769,743 +13%
MB
5
MPM BioImpact
Massachusetts
$12.7M +$945 +300 +0%
SCM
6
Suvretta Capital Management
New York
$12.5M -$945K -300,000 -7%
Morgan Stanley
7
Morgan Stanley
New York
$11.9M +$1.51M +478,003 +15%
Millennium Management
8
Millennium Management
New York
$11.6M +$3.85M +1,221,554 +52%
MAM
9
Monaco Asset Management
Monaco
$9.43M +$7.68M +2,439,494 +539%
NM
10
Newtyn Management
New York
$8.16M +$1.58M +502,863 +25%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$7.14M +$3.77M +1,196,925 +121%
JP Morgan Chase
12
JP Morgan Chase
New York
$6.84M +$2.8M +889,231 +74%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$6.24M -$366K -116,337 -6%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$5.85M +$962K +305,500 +20%
State Street
15
State Street
Massachusetts
$5.69M -$625K -198,380 -10%
Citadel Advisors
16
Citadel Advisors
Florida
$5.45M +$4.77M +1,514,877 +971%
Two Sigma Investments
17
Two Sigma Investments
New York
$5.25M -$364K -115,678 -7%
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$4.28M +$3.72M +1,181,931 +897%
Goldman Sachs
19
Goldman Sachs
New York
$4.14M -$959K -304,375 -19%
PM
20
Prosight Management
Texas
$4.13M -$985K -312,623 -20%
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$3.46M -$121K -38,534 -4%
Qube Research & Technologies (QRT)
22
Qube Research & Technologies (QRT)
United Kingdom
$3.31M -$1.68M -533,904 -34%
AQR Capital Management
23
AQR Capital Management
Connecticut
$2.85M +$301K +95,579 +12%
TCM
24
Tang Capital Management
California
$2.77M – – –
Charles Schwab
25
Charles Schwab
California
$2.43M +$407K +129,313 +21%
1
2 3 4 5

RCKT Hedge Fund Activity: Q3 2025 in Review

173 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2025, worth a combined $315M — up 35% from $233M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of RCKT and 28 opened new positions — a net loss of 22 holders — while 62 trimmed existing stakes and 61 added.

The largest buyer was Monaco Asset Management, adding an estimated $7.68M. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $2.69M sold.

  • 173 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2025, down from 196 in Q2 2025.
  • Funds reported $315M of Rocket Pharmaceuticals stock for Q3 2025, up 35% quarter-over-quarter.
  • 28 funds opened new Rocket Pharmaceuticals positions in Q3 2025 and 50 closed out, a net change of -22 holders.
  • The largest Rocket Pharmaceuticals buyer in Q3 2025 was Monaco Asset Management, an estimated $7.68M added.
  • The largest Rocket Pharmaceuticals seller in Q3 2025 was Toronto Dominion Bank, an estimated $2.69M sold.

Based on aggregated 13F filings for Q3 2025.